MedPath

Polyethylene glycol

Generic Name
Polyethylene glycol
Brand Names
Bi-peglyte, Clearlax, Colyte, Gavilax, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Gentlelax, Gialax, Glycolax, Golytely, Healthylax, Miralax, Moviprep, Nulytely, Peglyte, Pegylax, Plenvu, Purelax, Suflave
Drug Type
Small Molecule
CAS Number
25322-68-3
Unique Ingredient Identifier
3WJQ0SDW1A
Background

Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage. PEGs are water-soluble polymers that can form hydrogen bonds in a ratio of 100 water molecules per one PEG molecule. Molecular weights of PEGs vary by time of the polymerization process and the molecular weight represents the weighted average of the individual PEG molecules. PEGs differ in their physical and chemical properties depending on their molecular weight: PEGs are liquids when molecular weights are <1000 and the molecule turns to waxy solids with increasing molecular weights. The most common preparations of PEGs include PEG 3350 and PEG 400. PEGs have various applications in many fields, ranging from medical to industrial areas. PEGs have a long history of gastroenterology: PEG 3350 is a common over-the-counter osmotic laxative used to relieve occasional constipation. PEG 3350 is also used for cleansing of the colon in preparation for colonoscopy in adults.

The rationale of using PEG in gastroenterology is due to the physical properties of the compound: its potent water-binding capacity, negligible intestinal absorption with increasing molecular mass, lack of significant toxicity, and limited intestinal enzymatic degradation or bacterial metabolism all make PEG a useful therapeutic agent for the treatment of occasional constipation and bowel cleansing for preparation in colonoscopy.

Indication

Polyethylene glycol is indicated for use as an over-the-counter osmotic laxative to relieve occasional constipation. When used in combination with sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride, it is used for cleansing of the colon in preparation for colonoscopy in adults.

Associated Conditions
Chronic Constipation, Constipation, Dry Eye Syndrome (DES), Dry Eyes, Occasional Constipation
Associated Therapies
Bowel preparation therapy, Eye lubrication

Evaluation of the Performance of Two Neutral Oral Contrast Agents in CT Enterography

Not Applicable
Conditions
CTE
Interventions
First Posted Date
2018-04-12
Last Posted Date
2018-08-24
Lead Sponsor
Shandong University
Target Recruit Count
60
Registration Number
NCT03495804
Locations
🇨🇳

Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China

Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

First Posted Date
2018-03-26
Last Posted Date
2022-02-09
Lead Sponsor
Children's Hospital of Philadelphia
Target Recruit Count
10
Registration Number
NCT03476317
Locations
🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Stability of the Microbiome in IBD and IBS

Not Applicable
Completed
Conditions
Microbiota
Interventions
First Posted Date
2018-01-10
Last Posted Date
2020-08-11
Lead Sponsor
Medical University of Graz
Target Recruit Count
50
Registration Number
NCT03395548
Locations
🇦🇹

Universitätsklinikum Graz, Graz, Styria, Austria

Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy

Phase 4
Conditions
Adenoma Detection Rate
Bowel Preparation Scale
the Amount of Air Bubble
Interventions
Drug: 3L PEG+Dyclonine Hydrochloride Mucilage
First Posted Date
2017-11-24
Last Posted Date
2017-11-24
Lead Sponsor
Changhai Hospital
Target Recruit Count
580
Registration Number
NCT03352700
Locations
🇨🇳

Changhai Hospital, Second Military Medical University, Shanghai, China

A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects

Phase 2
Completed
Conditions
Colonoscopy
Interventions
First Posted Date
2017-11-01
Last Posted Date
2023-10-24
Lead Sponsor
Braintree Laboratories
Target Recruit Count
121
Registration Number
NCT03328507
Locations
🇺🇸

Braintree Research Site 3, Chula Vista, California, United States

🇺🇸

Braintree Research Site 1, Anaheim, California, United States

🇺🇸

Braintree Clinical Research Site 2, Ogden, Utah, United States

and more 1 locations

Effect of PEG, Bisacodyl and Prucalopride on Colonic Motility in Healthy Subjects

Phase 4
Completed
Conditions
Chronic Constipation
Interventions
First Posted Date
2017-09-12
Last Posted Date
2017-09-12
Lead Sponsor
University Hospital, Gasthuisberg
Target Recruit Count
10
Registration Number
NCT03279341
Locations
🇧🇪

TARGID, Leuven, Belgium

Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

Phase 1
Terminated
Conditions
Advanced Solid Cancers
Interventions
First Posted Date
2017-08-18
Last Posted Date
2022-04-27
Lead Sponsor
Polaris Group
Target Recruit Count
33
Registration Number
NCT03254732
Locations
🇨🇳

Facility National Cheng Kung University, Tainan, Taiwan

Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Ultra Preservative Free (087LATAMFIV)

Phase 4
Completed
Conditions
Dry Eye Syndrome
Interventions
First Posted Date
2017-07-21
Last Posted Date
2019-10-31
Lead Sponsor
Laboratorios Sophia S.A de C.V.
Target Recruit Count
326
Registration Number
NCT03223909
Locations
🇲🇽

Fernando Rodriguez Sixtos Higuera, Irapuato, Guanajuato, Mexico

Peritoneal Dialysis Pilot Study: Evaluating Polyethylene Glycol (PEG) for Constipation

Phase 4
Completed
Conditions
Constipation
Peritoneal Dialysis Complication
Interventions
Drug: Current Bowel Protocol (senna/lactulose)
First Posted Date
2017-05-10
Last Posted Date
2024-08-21
Lead Sponsor
Nova Scotia Health Authority
Target Recruit Count
25
Registration Number
NCT03148002
Locations
🇨🇦

Queen Elizabeth Health Sciences Centre, Halifax, Nova Scotia, Canada

To Study the Efficacy of PEG-IFN Alpha in HBeAg Negative Chronic Hepatitis B Patients After Stopping Nucleotide Analogue Therapy.

Not Applicable
Conditions
Hepatitis B
Interventions
First Posted Date
2017-04-21
Last Posted Date
2020-02-05
Lead Sponsor
Institute of Liver and Biliary Sciences, India
Target Recruit Count
118
Registration Number
NCT03123653
Locations
🇮🇳

Institute of Liver and Biliary Sciences, New Delhi, Delhi, India

© Copyright 2025. All Rights Reserved by MedPath